Hypertension
Conditions
Keywords
High blood pressure, HIV
Brief summary
The aim of the study is to investigate the neural underpinnings of cardiovascular reactivity to mental stress as a function of HIV and hypertensive risk.
Detailed description
The main objectives of the study are to assess (1) patterns of brain activity/connectivity that confers greater cardio-autonomic/emotion regulation, (e.g., heart rate variability, blood pressure reactivity, inflammatory-immune activation, etc.), during rest, mental stress, and anger-related distress, (2) whether changes in breathing pace mitigate task-based effects on cardio-autonomic-immune regulation, and (3) whether these patterns vary as a function of HIV or pre-hypertensive (HTN) status-related changes to the brain structures underlying cardioautonomic and emotion regulation.
Interventions
BEHAVIORALPaced breathing
Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
BEHAVIORALActive relaxation
Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
University of Miami
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. pre-hypertension screening. 2. HIV-antibody testing.
Exclusion criteria
1. current use of anti-lipid, antihypertensive, or heart rate altering medications; 2. current or lifetime history of cardiovascular disease diagnosis or treatment including pulmonary stenosis, heart valve abnormalities and hypertension; 3. current or lifetime diagnoses of cancer, kidney/liver disease, hypertension, Type 1 or Type 2 diabetes; 4. history of trauma, cerebral infarction or hemorrhage; 5. current diagnosis and/or treatment for hypertension; 6. severe cognitive impairment; 7. current treatment or diagnosis of psychiatric illness; 8. metal implants or debris within the body; or pregnancy; 9. body mass index \> 35; 10. use of hormone replacement therapy; and current smoker.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in heart rate variability | Baseline, pre-intervention and up to 60 minutes post-intervention | Heart rate variability will be measured using a standard electrocardiogram to detect variability in R -to-R intervals. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in cytokine expression in peripheral blood mononuclear cells | Baseline, pre-intervention and up to 60 minutes post-intervention | Peripheral blood will be drawn and mononuclear cells isolated and incubated with lipopolysaccharide to induce inflammatory cytokine expression. The change in cytokine expression will be quantified as a function of time. |
Countries
United States
Outcome results
None listed